## CLAIMS

We claim:

1. A method of treating cancer in a subject in need thereof, comprising administering an effective amount of Conjugate **1** or a pharmaceutically acceptable salt thereof to the subject at a dose of 150 mg/m$^2$, 175 mg/m$^2$, or 200 mg/m$^2$ body surface area.

2. A method of treating cancer in a subject in need thereof, comprising administering an effective amount of Conjugate **1** or a pharmaceutically acceptable salt thereof to the subject, wherein the subject has received at least one previous anticancer therapy.

3. A method of treating cancer in a subject in need thereof, comprising administering an effective amount of Conjugate **1** or a pharmaceutically acceptable salt thereof to the subject, wherein the subject shows partial response or stable disease after the treatment.

4. The method of any one of claims 1, 2 or 3, wherein the dose of Conjugate **1** or a pharmaceutically acceptable salt thereof is 175 mg/m$^2$.

5. The method of claim 4, wherein Conjugate **1** or a pharmaceutically acceptable salt thereof is administered once a week for 3 weeks on Day 1, Day 8, and Day 15 followed with one week of no treatment.

6. The method of any one of claims 1, 2 or 3, wherein the cancer is selected from the group consisting of a cancer of anus, breast, cholangiocarcinoma, colon, Ewing sarcoma, liver, lung, neuroendocrine, ovary, pancreas, salivary gland, and sarcoma.

7. The method of any one of claims 1, 2 or 3, wherein the cancer is pancreatic adenocarcinoma, endometrial adenocarcinoma, liposarcoma, or squamous cell carcinoma of the anus, cervix, or head and neck.

8. The method of any one of claims 1, 2 or 3, wherein the ratio of the tumor Conjugate **1** level to the plasma Conjugate **1** level is more than 5.

9. The method of any one of claims 1, 2 or 3, wherein the tumor Conjugate **1** level is more than 300 nM.

10. The method of any one of claims 1, 2 or 3, wherein the ratio of the tumor SN-38 level to the plasma SN-38 level is more than 3.

11. The method of any one of claims 1, 2 or 3, wherein the tumor SN-38 level is more than 80 nM.

12. The method of claim 1, wherein the subject further receives at least one PARP inhibitor treatment.

13. The method of claim 12, wherein the PARP inhibitor is administered on Days 2, 3, 4, 5 and 6 of a 7-day cycle.

14. The method of claim 12, wherein the PARP inhibitor is talazoparib.

15. The method of claim 12, wherein the cancer is small cell lung cancer.

16. The method of claim 12, wherein the subject is HPV positive.

17. The method of claim 1, wherein the subject further receives 5-FU, leucovorin, or a combination of 5-FU and leucovorin.